ORAGENICS, INC. Sale of Stock, Consideration Received on Transaction
ORAGENICS, INC. (OGEN) reported Sale of Stock, Consideration Received on Transaction of $7.70 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Notes › Equity
us-gaap:SaleOfStockConsiderationReceivedOnTransaction · last filed 2024-11-13
- ORAGENICS, INC. sale of stock, consideration received on transaction for the quarter ending 2024-09-30 was $4.50M.
| Period end | Sale of Stock, Consideration Received on Transaction 3 month | Sale of Stock, Consideration Received on Transaction 6 month | Sale of Stock, Consideration Received on Transaction 9 month |
|---|---|---|---|
| 2024-09-30 | $4.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $7.70M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $3.20M 10-Q · filed 2024-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |